Gilead shares are trading lower after the company's Phase 3 TROPiCS-04 study missed its primary endpoint of overall survival.
Gilead Sciences, Inc. +2.17%
Gilead Sciences, Inc. GILD | 88.16 | +2.17% |
Gilead shares are trading lower after the company's Phase 3 TROPiCS-04 study missed its primary endpoint of overall survival.